
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>Acetylsalicylic acid</td><td>Acarbose</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Acarbose.</td></tr><tr><td>Barnidipine</td><td>Acarbose</td><td>The risk or severity of hypoglycemia can be increased when Barnidipine is
combined with Acarbose.</td></tr><tr><td>Barnidipine</td><td>Acetylsalicylic acid</td><td>The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid
is combined with Barnidipine.</td></tr><tr><td>Barnidipine</td><td>Bictegravir</td><td>The metabolism of Bictegravir can be decreased when combined with Barnidipine.</td></tr><tr><td>Barnidipine</td><td>Gliclazide</td><td>The risk or severity of hypoglycemia can be increased when Barnidipine is
combined with Gliclazide.</td></tr><tr><td>Barnidipine</td><td>Irbesartan</td><td>Irbesartan may increase the antihypertensive activities of Barnidipine.</td></tr><tr><td>Barnidipine</td><td>Sitagliptin</td><td>The metabolism of Sitagliptin can be decreased when combined with Barnidipine.</td></tr><tr><td>Calcitriol</td><td>Barnidipine</td><td>The metabolism of Calcitriol can be decreased when combined with Barnidipine.</td></tr><tr><td>Emtricitabine</td><td>Metformin</td><td>The excretion of Emtricitabine can be decreased when combined with Metformin.</td></tr><tr><td>Gliclazide</td><td>Acarbose</td><td>The risk or severity of hypoglycemia can be increased when Acarbose is combined
with Gliclazide.</td></tr><tr><td>Gliclazide</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Gliclazide.</td></tr><tr><td>Irbesartan</td><td>Acetylsalicylic acid</td><td>The risk or severity of renal failure, hyperkalemia, and hypertension can be
increased when Irbesartan is combined with Acetylsalicylic acid.</td></tr><tr><td>Irbesartan</td><td>Gliclazide</td><td>The metabolism of Gliclazide can be decreased when combined with Irbesartan.</td></tr><tr><td>Metformin</td><td>Acarbose</td><td>The serum concentration of Metformin can be decreased when it is combined with
Acarbose.</td></tr><tr><td>Metformin</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Metformin.</td></tr><tr><td>Metformin</td><td>Barnidipine</td><td>The risk or severity of hypoglycemia can be increased when Barnidipine is
combined with Metformin.</td></tr><tr><td>Metformin</td><td>Bictegravir</td><td>The excretion of Metformin can be decreased when combined with Bictegravir.</td></tr><tr><td>Metformin</td><td>Nebivolol</td><td>The therapeutic efficacy of Metformin can be increased when used in combination
with Nebivolol.</td></tr><tr><td>Metformin</td><td>Pentoxifylline</td><td>Metformin may decrease the excretion rate of Pentoxifylline which could result
in a higher serum level.</td></tr><tr><td>Metformin</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Metformin.</td></tr><tr><td>Nebivolol</td><td>Acarbose</td><td>The therapeutic efficacy of Acarbose can be increased when used in combination
with Nebivolol.</td></tr><tr><td>Nebivolol</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of Nebivolol.</td></tr><tr><td>Nebivolol</td><td>Barnidipine</td><td>Nebivolol may increase the antihypertensive activities of Barnidipine.</td></tr><tr><td>Nebivolol</td><td>Gliclazide</td><td>The therapeutic efficacy of Gliclazide can be increased when used in combination
with Nebivolol.</td></tr><tr><td>Nebivolol</td><td>Irbesartan</td><td>Irbesartan may increase the hypotensive activities of Nebivolol.</td></tr><tr><td>Nebivolol</td><td>Sitagliptin</td><td>The therapeutic efficacy of Sitagliptin can be increased when used in
combination with Nebivolol.</td></tr><tr><td>Pentoxifylline</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may increase the antiplatelet activities of Pentoxifylline.</td></tr><tr><td>Pentoxifylline</td><td>Irbesartan</td><td>Pentoxifylline may increase the hypotensive activities of Irbesartan.</td></tr><tr><td>Pentoxifylline</td><td>Nebivolol</td><td>Pentoxifylline may increase the hypotensive activities of Nebivolol.</td></tr><tr><td>Pentoxifylline</td><td>Sitagliptin</td><td>Pentoxifylline may decrease the excretion rate of Sitagliptin which could result
in a higher serum level.</td></tr><tr><td>Rosuvastatin</td><td>Acarbose</td><td>The therapeutic efficacy of Acarbose can be increased when used in combination
with Rosuvastatin.</td></tr><tr><td>Rosuvastatin</td><td>Barnidipine</td><td>The metabolism of Rosuvastatin can be decreased when combined with Barnidipine.</td></tr><tr><td>Rosuvastatin</td><td>Calcitriol</td><td>The metabolism of Rosuvastatin can be increased when combined with Calcitriol.</td></tr><tr><td>Rosuvastatin</td><td>Gliclazide</td><td>The therapeutic efficacy of Gliclazide can be increased when used in combination
with Rosuvastatin.</td></tr><tr><td>Rosuvastatin</td><td>Irbesartan</td><td>The metabolism of Rosuvastatin can be decreased when combined with Irbesartan.</td></tr><tr><td>Rosuvastatin</td><td>Sitagliptin</td><td>The excretion of Sitagliptin can be decreased when combined with Rosuvastatin.</td></tr><tr><td>Sitagliptin</td><td>Acarbose</td><td>The risk or severity of hypoglycemia can be increased when Acarbose is combined
with Sitagliptin.</td></tr><tr><td>Sitagliptin</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Sitagliptin.</td></tr><tr><td>Sitagliptin</td><td>Gliclazide</td><td>Sitagliptin may increase the hypoglycemic activities of Gliclazide.</td></tr><tr><td>Sitagliptin</td><td>Irbesartan</td><td>The metabolism of Sitagliptin can be decreased when combined with Irbesartan.</td></tr><tr><td>Tenofovir alafenamide</td><td>Acetylsalicylic acid</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Acetylsalicylic acid.</td></tr><tr><td>Tenofovir alafenamide</td><td>Barnidipine</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Barnidipine.</td></tr><tr><td>Tenofovir alafenamide</td><td>Calcitriol</td><td>The metabolism of Tenofovir alafenamide can be increased when combined with
Calcitriol.</td></tr><tr><td>Tenofovir alafenamide</td><td>Irbesartan</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Irbesartan.</td></tr><tr><td>Tenofovir alafenamide</td><td>Pentoxifylline</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Pentoxifylline.</td></tr><tr><td>Tenofovir alafenamide</td><td>Rosuvastatin</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Rosuvastatin.</td></tr><tr><td>Tenofovir alafenamide</td><td>Sitagliptin</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Sitagliptin.</td></tr></tbody></table></div>
